Adaptimmune Therapeutics Plc ADR [NASDAQ: ADAP] traded at a low on Friday, posting a -7.87 loss after which it closed the day’ session at $1.17.
The results of the trading session contributed to over 13973796 shares changing hands. Over the past one week, the price volatility of Adaptimmune Therapeutics Plc ADR stands at 13.45% while the volatility over the past one month is 10.74%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for ADAP stock reached $298.93 million, with 227.17 million shares outstanding and 226.11 million shares in the current float. Compared to the average trading volume of 1.75M shares, ADAP reached a trading volume of 13973796 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Adaptimmune Therapeutics Plc ADR [ADAP]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ADAP shares is $3.02 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ADAP stock is a recommendation set at 1.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Adaptimmune Therapeutics Plc ADR shares, keeping their opinion on the stock as Buy, with their previous recommendation back on July 30, 2024. While these analysts kept the previous recommendation, Scotiabank raised their target price to Sector Outperform. The new note on the price target was released on May 30, 2024, representing the official price target for Adaptimmune Therapeutics Plc ADR stock. Previously, the target price had yet another raise to $3.60, while Bryan Garnier analysts kept a Buy rating on ADAP stock.
The Average True Range (ATR) for Adaptimmune Therapeutics Plc ADR is set at 0.12, with the Price to Sales ratio for ADAP stock in the period of the last 12 months amounting to 16.31. The Price to Book ratio for the last quarter was 12.26, with the Price to Cash per share for the same quarter was set at 0.56.
How has ADAP stock performed recently?
Adaptimmune Therapeutics Plc ADR [ADAP] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -15.83. With this latest performance, ADAP shares gained by 14.71% in over the last four-week period, additionally plugging by 17.00% over the last 6 months – not to mention a rise of 32.80% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ADAP stock in for the last two-week period is set at 47.14, with the RSI for the last a single of trading hit 41.28, and the three-weeks RSI is set at 49.48 for Adaptimmune Therapeutics Plc ADR [ADAP]. The present Moving Average for the last 50 days of trading for this stock 1.1022, while it was recorded at 1.2880 for the last single week of trading, and 0.9995 for the last 200 days.
Adaptimmune Therapeutics Plc ADR [ADAP]: Deeper insight into the fundamentals
Adaptimmune Therapeutics Plc ADR’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.81 and a Current Ratio set at 2.81.
Earnings analysis for Adaptimmune Therapeutics Plc ADR [ADAP]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ADAP. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Adaptimmune Therapeutics Plc ADR go to 1.00%.
Insider trade positions for Adaptimmune Therapeutics Plc ADR [ADAP]
The top three institutional holders of ADAP stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.5034%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $178.43 billion in ADAP stocks shares; and BERKSHIRE HATHAWAY INC, currently with $135.36 billion in ADAP stock with ownership which is approximately 5.1238%.
